How to Prepare for Europe’s New Assessment Timeline
If there’s one part of the new EU HTA Regulation that consistently catches companies off guard, it’s the timeline. Not the complexity of the evidence, not the methodology of indirect comparisons, not even the unpredictability of comparators — but the sheer speed with which the Joint Clinical Assessment (JCA) moves once the process begins.
From that moment, time becomes the constraint that governs everything else.
In brief: The fastest way to lose control of the JCA timeline is to treat it as a writing sprint. When scope arrives, the work isn’t just assembling documents—it’s reconciling unresolved decisions about comparators, endpoints, evidence gaps, and who owns what. Locking these decisions early turns the 100‑day window into execution rather than late-stage problem‑solving.
The Moment the Clock Starts
Here’s the reality: once the EMA validates your Marketing Authorization Application, the HTA assessors will define the JCA PICO (population, intervention, comparator, outcomes) analysis scope. And the moment that scope arrives, possibly with multiple PICOs, depending on your indication, you have 100 days to produce a complete, aligned, defensible dossier.
One hundred days.
No extensions.
No pauses.
No chance to collect new evidence.
This JCA 100-day timeline is unforgiving. Readiness has to start well before the clock begins.
Many teams treat the 100-day window as workable until they see how quickly it moves without early preparation. By then, the room to adjust is gone.
Why the JCA Timeline Is So Demanding
JCA doesn’t reduce the burden of evidence review. Instead, it sets clearer expectations upfront through a structured dossier focused on completeness, transparency, and justification. That means teams must be ready to deliver:
- Separate analyses and reporting for each PICO
- Transparent evidence selection (what was included, what was not, and why)
- Clear justification of comparators and comparison methods (including indirect approaches where needed)
- Explicit documentation of uncertainty and limitations (risk of bias, evidence gaps, and impact on certainty)
And none of this is developed at the end. It must be ready the moment the final JCA PICO scope arrives. Teams that haven’t prepared early often find themselves working under intense time pressure. Common issues include incomplete comparator readiness, limited early understanding of treatment patterns across EU markets (critical for building realistic PICO scenarios), endpoints that don’t map cleanly to HTA decision-making, or analysis plans that are difficult to adapt for indirect comparisons.
As a result, many submissions are expected to enter the 100-day window with evidence packages that are only partially aligned to the final assessment scope.
JCA Shapes Development Strategy
What determines whether a company moves smoothly through the JCA is not what happens during the formal assessment window. It’s what they do in the months — ideally years — before the clock starts.
Teams who succeed treat the JCA not as a tick box, but as a development milestone. They anticipate comparators early. They model multiple PICOs. They understand the subtleties of clinical practice across Europe. They embed HTA thinking into their clinical protocols before pivotal trials begin.
And perhaps most importantly, they build internal governance that allows clinical, regulatory, medical, HEOR, and biostatistics to collaborate with urgency and clarity.
What We See in Practice
Teams that begin early have already mapped likely comparators, understood relevant subpopulations, and planned analyses that can support indirect comparisons. They arrive with a coherent evidence package and a clear rationale for the decisions they made.
Teams that begin later often discover gaps they cannot close at pace — absent comparator data, endpoints not aligned with HTA expectations, or analyses that were never built to support an ITC.
The distinction is not capability.
It is how much of this work was in place before the process started.
A Path Forward
Across markets, decision-makers are increasingly focused on added value versus standard of care. JCA brings that thinking forward in time, strengthening development strategy well beyond the European assessment. The new HTA landscape rewards proactive planning. The more a company can align evidence, operations, and strategy before the JCA begins, the more confident they become when the clock starts, because they’ve already done the hardest work.
We help companies build those systems early, with intention and a clear understanding of what the EU expects.
It’s the difference between surviving the JCA timeline… and leading it.
Related reading
Explore the guide: EU HTA Regulation guide
Continue reading: Next: The PICO problem
